Rhino-Conjunctivitis - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 76
Inquire Before Buying

Rhino-Conjunctivitis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 9 and 8 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Rhino-Conjunctivitis - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rhino-Conjunctivitis - Overview
Rhino-Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rhino-Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergopharma GmbH & Co KG
Allergy Therapeutics Plc
ASIT Biotech SA
Astellas Pharma Inc
Bial - Portela & Ca SA
Faes Farma SA
HAL Allergy BV
Laboratorios LETI SL
Oxagen Ltd
Rhino-Conjunctivitis - Drug Profiles
Acaroid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhino conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergovac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bilastine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hdm-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Birch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Timapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rhino-Conjunctivitis - Dormant Projects
Rhino-Conjunctivitis - Discontinued Products
Rhino-Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Feb 12, 2018: Completion of recruitment in PQ Grass Phase II trial
Jan 09, 2018: Allergy Therapeutics: PQ Birch Phase III clinical trial completes recruitment
Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial
May 30, 2017: ASIT biotech to disclose the detailed results of its phase III clinical study with gp-ASIT+ at EAACI 2017
Nov 30, 2015: Allergy Therapeutics Completes Patient Enrolment For Birch Study
May 18, 2014: BioTech Tools will be present at the EAACI congress
Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultra short Grass Allergy Vaccine by Allergy Therapeutics
Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil
Nov 28, 2011: Allergy Therapeutics Submits Complete Response to PEI In Germany And Clinical Study Protocol To FDA
Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study
Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain
Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries
Dec 02, 2010: Faes Farma: Bilastine is approved in eight European countries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Rhino-Conjunctivitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Rhino-Conjunctivitis - Pipeline by ALK-Abello AS, H1 2018
Rhino-Conjunctivitis - Pipeline by Allergopharma GmbH & Co KG, H1 2018
Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H1 2018
Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H1 2018
Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H1 2018
Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H1 2018
Rhino-Conjunctivitis - Pipeline by Faes Farma SA, H1 2018
Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2018
Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H1 2018
Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H1 2018
Rhino-Conjunctivitis - Dormant Projects, H1 2018
Rhino-Conjunctivitis - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Rhino-Conjunctivitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Zinc Lactate Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Zinc lactate is a zinc salt of lactic acid and commonly used ingredient in toothpaste, mouthwash, chewing gums and other oral hygiene products. Scope of the Report: The demand for zinc lactate has been steadily increasing on the backdrop of increasing health concerns across the globe. The worldwide market for Zinc Lactate is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to......
  • Global Tetanus Toxoid Vaccine Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. Scope of the Report: US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The worldwide market for Tetanus Toxoid Vaccine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. ......
  • Global Mental Illness Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Mental Illness is a psychological anomaly that is reflected in patient's behavior through disability, distress, or any conduct that is not considered as normal mental development. The causes of mental lllness are very diverse and often unclear in most cases. Scope of the Report: The worldwide market for Mental Illness Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a ne......
  • Global Ovarian Cancer Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 123
    Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. Scope of the Report: The worldwide market for Ovarian Cancer Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Ovarian Cancer Treatmen......
  • Global Pain and Fever Relief Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 120
    The demand for Pain and Fever Relief Drugs will continue to grow in the next few years. Scope of the Report: The worldwide market for Pain and Fever Relief Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Pain and Fever Relief Drugs in global market, especially in North America, Europe and Asia-Pac......
  • Global Pediatric Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 137
    The market for pediatric pharmaceuticals has become an increasingly important tool in life-cycle management. However, line extensions using children's formulations to increase patent life of existing adult dose drugs are only one of the drivers of this large, but little-studied market. Scope of the Report: The worldwide market for Pediatric Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in ......
  • Global Pneumonia Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing. A variety of organisms, including bacteria, viruses and fungi, can cause pneumonia. Scope of the Report: The worldwide market for Pneumonia Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from ......
  • Global Prostate Cancer Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 117
    Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Scope of the Report: The worldwide market for Prostate Cancer Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Prostate Cancer Treatment ......
  • Global Tuberculosis Treatment Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Nov-2018        Price: US 3480 Onwards        Pages: 122
    Tuberculosis (TB) is a disease caused by bacteria called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes, or talks. Scope of the Report: The worldwide market for Tuberculosis Treatment Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs